

By Electronic Submission

May 6, 2025


Bureau of Industry and Security
Office of Strategic Industries
U.S. Department of Commerce
1401 Constitution Ave NW
Washington, DC 20230

RE: DOCKET NO. 250414-0065; XRIN 0694-XC120; “NOTICE OF REQUEST FOR PUBLIC COMMENTS ON SECTION 232 NATIONAL SECURITY INVESTIGATION OF IMPORTS OF PHARMACEUTICALS AND PHARMACEUTICAL INGREDIENTS,” FEDERAL REGISTER VOL. 90, NO. 72; APRIL 16, 2025


I am writing today on behalf of Perspective Therapeutics, Inc. (“Perspective Therapeutics,” “we” or the “Company”) to provide comments regarding Notice of Request for Public Comments on Section 232 National Security Investigation of Imports of Pharmaceuticals and Pharmaceutical Ingredients, Federal Register Vol. 90, No. 72; April 16, 2025.

Perspective Therapeutics is a radiopharmaceutical company pioneering advanced treatments for cancers throughout the body. The Company has proprietary technology that utilizes the alpha-emitting isotope ²¹²Pb to deliver powerful radiation specifically to cancer cells via specialized targeting moieties. Our melanoma, neuroendocrine tumor, and solid tumor programs are in Phase 1/2a imaging and therapy trials in the U.S., and we are growing our regional network of drug product manufacturing facilities in the U.S., enabled by our proprietary ²¹²Pb generator, to deliver patient-ready products for clinical trials and commercial operations.

We are a U.S.-based radiopharmaceutical company leveraging research initially conducted at the University of Iowa. We currently produce in the U.S. all of the doses used in our innovative clinical trials to treat cancer patients at clinical centers in the U.S. We currently have two active manufacturing sites – one in Iowa and one in New Jersey – and we have purchased buildings to enable us to build out three additional manufacturing sites to deliver our treatments to patients throughout the U.S.



Perspective Therapeutics appreciates the Administration’s focus on strengthening domestic manufacturing and encourages continued interagency support, funding, and coordination to expand a sustainable and reliable U.S.-based supply chain.



Therefore, we urge the Administration to defer tariffs on specialized equipment that will enable us to expand our manufacturing of radiopharmaceutical treatments in the U.S. and the jobs associated with that manufacturing infrastructure until sufficient domestic manufacturing capabilities and supply are established, in order to sustain investment in U.S. manufacturing capabilities and research and development and expand access among cancer patients in the U.S.

Respectfully submitted,

/s/ Johan (Thijs) Spoor

Johan (Thijs) Spoor
Chief Executive Officer